August 29, 2014 -- BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
This study could potentially meet all of the criteria for FDA’s Animal Rule, a path by which drugs tested in animals could move to emergency treatment of humans while human safety trials proceed concomitantly.
The company, based in Research Triangle Park, North Carolina, is developing agents first identified in the laboratory of Yarligadda S. Babu, Ph.D., previously with the University of Alabama at Birmingham.
Help employers find you! Check out all the jobs and post your resume.
